PMID- 37852558 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240131 IS - 1535-6280 (Electronic) IS - 0146-2806 (Linking) VI - 49 IP - 1 Pt C DP - 2024 Jan TI - Adding Surgical Edge-to-Edge Mitral Valve Repair to Myectomy in Hypertrophic Obstructive Cardiomyopathy: Long-Term Functional and Echocardiographic Outcome. PG - 102134 LID - S0146-2806(23)00551-0 [pii] LID - 10.1016/j.cpcardiol.2023.102134 [doi] AB - This study evaluates the early and long-term clinical and echocardiographic outcome of edge-to-edge (E2E) mitral valve repair (MVr) concomitant to septal myectomy (SM) in patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM). A retrospective single-center analysis was performed of patients who underwent isolated SM or SM with E2E MVr from 2011 to 2022. Exclusion criteria were primary mitral valve (MV) disease or concomitant valve surgery. Early and long-term safety, functional and echocardiographic outcomes were compared between groups. Between January 2011 and April 2022, 76 consecutive patients underwent SM for HOCM: 42 patients (55%) underwent SM without additional E2E MVr (Group 1) and 34 patients (45%) underwent SM with additional E2E MVr (Group 2). At latest follow-up, 87% of patients were in New York Heart Association (NYHA) class I-II with no significant differences in NYHA class between groups. Incidence of safety events was comparable between groups. Echocardiographic relief of left ventricular outflow tract (LVOT) obstruction was comparable at early follow-up (P = 0.68), with a significant but small difference in maximum LVOT pressure gradient at latest follow-up in favor of E2E MVr (P = 0.04). Furthermore, patients who underwent SM with E2E MVr showed less residual systolic anterior motion at early and latest follow-up (P = 0.020; P = 0.178). Reintervention on the MV was absent in both groups at 1 year and equally low at follow-up (P = 0.27). This study demonstrates that adding E2E MVr to septal myectomy is as safe as isolated myectomy for the treatment of HOCM. Moreover, the addition of E2E MVr is associated with similar excellent functional improvement and freedom from MV reintervention. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Hegeman, Romy R M J J AU - Hegeman RRMJJ AD - Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands; Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands. Electronic address: r.hegeman@antoniusziekenhuis.nl. FAU - Heeringa, Tijn AU - Heeringa T AD - Department of Cardiothoracic Surgery, Utrecht University Medical Center, Utrecht, The Netherlands. FAU - Beukers, Sophie H Q AU - Beukers SHQ AD - Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Van Kuijk, Jan Peter AU - Van Kuijk JP AD - Departement of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Guglielmo, Marco AU - Guglielmo M AD - Departement of Cardiology, Utrecht University Medical Center, Utrecht, The Netherlands. FAU - Ten Berg, Jurrien M AU - Ten Berg JM AD - Departement of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Swaans, Martin J AU - Swaans MJ AD - Departement of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands. FAU - Klein, Patrick AU - Klein P AD - Department of Cardiothoracic Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands; Department of Cardiothoracic Surgery, Amsterdam University Medical Center, Amsterdam, The Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20231017 PL - Netherlands TA - Curr Probl Cardiol JT - Current problems in cardiology JID - 7701802 SB - IM MH - Humans MH - Mitral Valve/diagnostic imaging/surgery MH - *Mitral Valve Insufficiency/diagnostic imaging/surgery MH - Retrospective Studies MH - Heart Septum/diagnostic imaging/surgery MH - Treatment Outcome MH - Echocardiography MH - *Heart Valve Diseases MH - *Cardiomyopathy, Hypertrophic/diagnostic imaging/surgery COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper EDAT- 2023/10/19 00:44 MHDA- 2023/12/17 09:43 CRDT- 2023/10/18 19:28 PHST- 2023/10/11 00:00 [received] PHST- 2023/10/14 00:00 [accepted] PHST- 2023/12/17 09:43 [medline] PHST- 2023/10/19 00:44 [pubmed] PHST- 2023/10/18 19:28 [entrez] AID - S0146-2806(23)00551-0 [pii] AID - 10.1016/j.cpcardiol.2023.102134 [doi] PST - ppublish SO - Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102134. doi: 10.1016/j.cpcardiol.2023.102134. Epub 2023 Oct 17.